AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01721343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo enhanced usual care with an RCM and PCM
Study NCT00254657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
Study NCT00994162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZCare/V1STA Negative Pressure Wound Therapy System
Description: Vacuum Source and dressing kit that generates negative pressure over the wound.
Study NCT00606528 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: None. This is an observational study.
Study NCT02091947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FMS (Magstim rapid2)
Description: 5 Hz FMS, over bilateral sacral roots.
Study NCT02091947 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FMS (Magstim rapid2)
Description: 5 Hz FMS, over bilateral sacral roots.
Study NCT00139841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine HCl
Description: Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
Study NCT01142193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL255
Study NCT01142193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00616291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
Study NCT00832312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone-oxygen mixture
Description: 10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
Study NCT00832312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: Injection of 1cc of saline into the knee joint
Study NCT04690712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy.
Study NCT00254657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04093752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04093752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT02621697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive motor training
Description: Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
Study NCT01381406 — intervention group
Intervention type: DRUG
Intervention: TIO
Description: Patients receiving tiotropium bromide at index within the study period.
Study NCT01381406 — intervention group
Intervention type: DRUG
Intervention: TIO+FSC
Description: Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
Study NCT02621697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotherapeutic conventional treatment
Description: Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
Study NCT02818335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Reference Fasted
Description: Administered Orally
Study NCT02818335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Test Fasted
Description: Administered Orally
Study NCT02818335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414 Test Fed
Description: Administered Orally
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Given IV
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane
Description: Given IV
Study NCT03485950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03485950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Given IV
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Given IV
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazobactam
Description: Given IV
Study NCT03485950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazobactam
Description: Given IV
Study NCT02929147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
Study NCT02929147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
Study NCT02929147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In the Group 3 the PCA will contain placebo.
Study NCT02808923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Description: Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller.
Study NCT02808923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
Study NCT03475069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom Designed Exercises
Study NCT03475069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plates Exercises
Study NCT03475069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics Exercises
Study NCT02448355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT swept source DRI-Atlantis, Topcon
Description: 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
Study NCT04156334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia
Description: QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
Study NCT01537094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01537094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 250 mg once daily
Study NCT01537094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 1,000 mg once daily
Study NCT03341234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml %0,25 bupivacaine
Study NCT00619944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine - lopinavir/ritonavir drug interaction
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
Study NCT03341234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously
Study NCT03341234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided block
Study NCT00619944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumefantrine only arm
Description: Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
Study NCT04481607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3454
Description: TQB3454 tablets is a small molecule oral drug.
Study NCT01510834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multibehavioral, Computerized Tailored Intervention STR2IVE
Description: All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
Study NCT04501835 — intervention group
Intervention type: OTHER
Intervention: Diagnostic and treatment evaluation
Description: No intervention, description of the diagnostic evaluation and the treatment
Study NCT02584777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: QD (Once a day)
Study NCT01268033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
Study NCT01268033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
Study NCT00912340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT00912340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT00820144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTB by nasal way
Study NCT00820144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of CTB by oral way
Description: absorption of CTB by oral way
Study NCT00820144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of dukoral by oral way
Description: absorption of dukoral by oral way
Study NCT00820144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: absorption of CTB by sublingual way
Description: absorption of CTB by sublingual way
Study NCT00334646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral GW679769
Description: 150mg oral, once daily on days 1-3
Study NCT00334646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Cyclophosphamide 500-700mg/m2
Description: IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
Study NCT02532426 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
Study NCT04254796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience, and Action (TARA)
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
Study NCT01779596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Study NCT01779596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00397878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT00397878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00657722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography and Computed Tomography
Description: Preoperative angiography and Computed Tomography
Study NCT03842215 — intervention group
Intervention type: DEVICE
Intervention: smart physical exam
Description: Use smart physical exam to collect functional performance
Study NCT03644108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex® ER 600 mg
Description: Single dose of Mucinex® 600 mg ER Bi-Layer tablet
Study NCT00192595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Study NCT00192595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
Study NCT03870009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARDS patients
Description: The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation
Study NCT03004976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
Study NCT03004976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
Study NCT01933321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous stem cell
Description: Mobilization and collection of stem cells for intravenous and intrathecal administration
Study NCT04499846 — intervention group
Intervention type: OTHER
Intervention: Therapeutic education
Description: Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
Study NCT00961441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days
Study NCT03617913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03617913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03617913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03617913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV
Study NCT03617913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03617913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT01143714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
Study NCT01143714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Petrolatum
Description: Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
Study NCT01767181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive light therapy
Description: Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
Study NCT01767181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
Study NCT01350050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: articaine
Description: Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections.
Study NCT01350050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 9% Sodium Chloride solution for injection
Description: 9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
Study NCT01807949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT01807949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet
Study NCT01807949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet
Study NCT02972957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasovac-S
Description: one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
Study NCT02972957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
Study NCT02474823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: polysomnogram
Description: all participants will undergo PSG for assessment of OSA
Study NCT02474823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: home sleep test
Description: all participants will undergo HST for assessment of OSA
Study NCT02474823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Easy Sleep Apnea Predictor
Description: all participants will undergo ESAP for assessment of OSA
Study NCT04083118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI
Description: Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
Study NCT04083118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Repeat 18F sodium fluoride PET/MRI
Description: as per first study visit but without the PET/CT
Study NCT00147992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants in totally edentate upper and lower jaw
Description: Immediate loading of implants in totally edentate upper and lower jaw.
Study NCT01061320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha tocopherol
Description: The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
Study NCT01061320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
Study NCT00161616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: InductOs
Description: InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
Study NCT00161616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: InductOs
Description: InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
Study NCT01247454 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: academic detailing
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.